The importance of superficial basal cell carcinoma in a retrospective study of 139 patients who underwent Mohs micrographic surgery in a Brazilian university hospital by Takata Pontes, Luciana et al.
The importance of superficial basal cell carcinoma in
a retrospective study of 139 patients who underwent
Mohs micrographic surgery in a Brazilian university
hospital
Luciana Takata Pontes,I Rafael Fantelli Stelini,II Maria Leticia Cintra,II Renata Ferreira Magalha˜es,I
Paulo Eduardo N.F. Velho,I Aparecida Machado MoraesI
IHospital das Clı´nicas da Universidade Estadual de Campinas, Clı´nica Me´dica, Divisa˜o Dermatologia, IIHospital das Clı´nicas da Universidade Estadual
de Campinas, Patologia, Sa˜o Paulo/ SP, Brazil.
OBJECTIVE:Mohs micrographic surgery is a specialized surgical procedure used to treat skin cancer. The purpose
of this study was to better understand the profile of the patients who underwent the procedure and to
determine how histology might be related to complications and the number of stages required for complete
removal.
METHODS: The records of patients who underwent Mohs micrographic surgery from October 2008 to November
2013 at the Dermatology Division of the Hospital of the Campinas University were assessed. The variables
included were gender, age, anatomical location, histology, number of stages required and complications.
RESULTS: Contingency tables were used to compare the number of stages with the histological diagnosis. The
analysis showed that patients with superficial basal cell carcinoma were 9.03 times more likely to require more
than one stage. A comparison between complications and histological diagnosis showed that patients with
superficial basal cell carcinoma were 6.5 times more likely to experience complications.
CONCLUSION: Although superficial basal cell carcinoma is typically thought to represent a less-aggressive
variant of these tumors, its propensity for demonstrating ‘‘skip areas’’ and clinically indistinct borders make it a
challenge to treat. Its particular nature may result in the higher number of surgery stages required, which may,
as a consequence, result in more complications, including recurrence. Recurrence likely occurs due to the
inadequate excision of the tumors despite their clear margins. Further research on this subtype of basal cell
carcinoma is needed to optimize treatments and decrease morbidity.
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’ INTRODUCTION
Mohs micrographic surgery (MMS) is a specialized surgical
procedure used to treat skin cancer that is commonly performed
on patients who present with a large tumor (42 cm), a high-
risk histological type tumor (for example, morpheaform,
infiltrative or micronodular basal cell carcinoma (BCC), poorly
differentiated squamous cell carcinoma (SCC), or a tumor with
perineural invasion), recurrent or incompletely excised tumors,
tumors located in the H zone of the face and lesions with
indistinct clinical borders (1,2).
This technique histologically maps the margins of the tumor
infiltration into the tissue while sparing healthy tissue, which
allows greater tissue conservation and margin control compared
with other surgical procedures (2). After mapping the excised
tissue and the surgical defect, the specimens are frozen and
stained to make histologic slides. If neoplastic cells are detected
on the slides, more tissue is excised at the exact location of the
remaining tumor tissue. The procedure is complete when no
evidence of neoplastic cells is detected in the frozen sections.
One of the objective measures of an MMS case is the
number of stages required for tumor clearance (3). ThisDOI: 10.6061/clinics/2015(11)01
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number is believed to be related to numerous factors,
including the anatomical site of the tumor; for example,
those located in cosmetically sensitive areas, such as the nose
tip and eyelid, can potentially require more stages. Other
factors include tumor histology, as in morpheaform BCC,
which displays a wider-than-visualized lateral spread in the
dermis (4-6). Tumor size alone is not believed to predispose
the patient to requiring more stages and well-demarcated
tumors can be removed in only one or a few stages (4).
As with any surgical procedure, there is a risk of post-
operative complications, most of which involve bleeding (1).
Other complications that have been described include
infection, flap or graft loss, unfavorable contours, scars and
delayed healing (5). In this study, we considered recurrence
to be a late complication.
The purpose of this study was to better understand MMS
patient profiles and to determine how the histology of
tumors might be related to the number of MMS stages
required and the complications of the procedure.
’ MATERIALS AND METHODS
The records of all of the patients who underwent MMS
from October 2008 to November 2013 at the Dermatology
Division of the Clinical Hospital at Campinas University
(HC-UNICAMP) were assessed.
If not all of the information necessary for the study was
included in a patient’s records, the patient was excluded.
The variables included were gender, age, anatomical location,
histology of the tumor, number of stages and complications.
Exploratory data analysis (EDA) was performed using a
frequency calculation. Logistic regression models were applied
to evaluate the risk factor for each response variable of interest.
For multiple factor analyses, a stepwise method was chosen to
select the variables. A 95% confidence level was used and the
statistical analyses were performed using the Statistical
Analysis System for Windows software, version 9.4 (SAS 9.4).
’ RESULTS
A total of 139 patients comprising 55 (39.57%) males and
84 (60.43%) females were included. Of these patients,
14 (10.07%) were 40 years or younger, 21 (15.11%) were 41
to 50 years old, 26 (18.71%) were 51 to 60 years old, 34
(24.46%) were 61 to 70 years old and 44 (31.65%) were 71 or
older (Table 1).
Table 2 presents the descriptive statistics for the anatomi-
cal location of the tumor. The nose was the most frequent
location, comprising 61.9% of the total patients, followed by
the periocular area, the nasolabial fold, the perilabial area,
the temporal/frontal area or the glabella, malar and ear.
Each tumor was histologically classified according to a prior
biopsy conducted previous to the MMS and then classified as
nodular BCC, superficial BCC, infiltrative-growth BCC, mor-
pheaform BCC, micronodular BCC, non-specified BCC, SCC,
trichoblastoma, dermatofibrosarcoma protuberans (DFSP),
fibrous histiocytoma and primary cutaneous adenocarcinoma.
Some lesions contained tissue of more than one histological
type in the same sample and this was taken into account in our
study (Table 3).
The patients underwent one to four surgery stages, with
four being the maximum number of stages required in all of
the included cases. Most of the patients (52.52%) underwent
only one MMS stage (Table 1).
The classification of complications was determined
according to postoperative results. They were divided into
no complication, bleeding, ectropion, microstomy, flap or
graft necrosis and recurrence (Table 1). We considered
recurrence a late complication to facilitate the study of the
variables.
There were four patients who experienced recurrence: two
had a superficial BCC (50%), one had a nodular BCC (25%)
and one had a morpheaform and infiltrative BCC (25%).
Contingency tables were used to compare the number of
MMS stages with the histological diagnosis. Table 4 presents
the simple and multiple logistic rank regressions used to
correlate the tumor histology with the number of stages
(p-valueo0.05). The individual analysis showed that patients
with a superficial BCC were 9.03 times more likely to require
more stages of surgery. When the risk factors were studied in
combination (multiple analysis), it was confirmed that the
patients with an increased risk of a higher number of MMS
stages were those who were diagnosed with superficial BCC.
The histological diagnoses that do not appear in Table 4 were
excluded due to the low number of cases.
Contingency tables were used to compare complications
with the histological diagnosis and age. Table 5 represents
the simple and multiple binary logistic regressions used to
evaluate the risk factors associated with complications
Table 1 - Descriptive statistics.
Variable N %
Gender
female 84 60.43%
male 55 39.57%
Age
p40 14 10.07%
41-50 21 15.11%
51-60 26 18.71%
61-70 34 24.46%
X71 44 31.65%
Stages
1 73 52.52%
2 50 35.97%
3 13 9.35%
4 3 2.16%
Complications
none 130 93.5%
recurrence 4 2.87%
bleeding 1 0.72%
ectropion 1 0.72%
microstomy 1 0.72%
flap or graft necrosis 2 1.44%
Table 2 - Anatomic location descriptive statistics.
Anatomical Location Frequency % of
patients
(n=139)
% of the total
anatomical
locations
(n=145)
Nose 86 61.9 42.7
Periocular 24 17.3 11.9
Nasolabial fold 9 6.5 4.5
Perilabial 8 5.8 4.0
Temporal, frontal or glabella 6 4.3 3.0
Malar 5 3.6 2.5
Other 4 2.9 2.0
Ear 3 2.2 1.5
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(p-valueo0.05). In the individual analysis, it was observed
that patients with superficial BCC were 6.5 times more likely
to experience complications.
Multiple analyses confirmed that superficial BCC was a
risk factor for complications and that there was no
correlation between complications and other histological
diagnoses or age. The histological diagnoses that do not
appear in Table 5 were not used due to the low number of
cases or because the patients did not present any post-
operative complications.
’ DISCUSSION
Because MMS surgery results in a high cure rate and
maximal preservation of the normal tissue, it is a valuable
treatment for many modalities of skin cancer. The cure rate for
patients who undergo MMS has been observed to be 99% for
primary BCC and 93% to 98% over a 3- to 5-year time frame
for recurrent BCC in several retrospective studies (1,6,7).
Superficial BCC is often considered to be a non-aggressive
form of BCC and it has been hypothesized that this type of
BCC has an increased likelihood of developing in the trunk, as
it often develops after intense but intermittent sun exposure (8).
Clinically, it tends to present as thin, pink, scaly plaques that
often have indistinct borders (Figure 1).
Histologically, it is unique because it consists of small nest
of basaloid cells connected to the epidermis with minimal
dermal involvement (Figure 2). The nests are intermixed
with normal, non-involved epidermis in a multifocal pattern.
These ‘‘skip areas’’ are probably what make this type of skin
cancer so difficult to treat (8).
The aggressive subtypes of BCC (infiltrative, morpheaform,
micronodular and metatypical) are known to require more MMS
stages to achieve tumor-free margins (3,9). Batra et al. published
a retrospective analysis of 1095 MMS cases that displayed high-
risk factors that were associated with extensive tumor spread,
which was defined as a requirement of at least 3 MMS stages. It
was determined that the predictive characteristics included any
BCC on the nose, morpheaform BCC on the cheek, neck tumors
and recurrent BCC in men, location on the eyelid, temple, or ear
helix and a size410 mm (10).
In our study, we found the superficial BCC tumor type
requires a higher number of stages for removal. We believe
that the main reason for this finding is the difficulty of
clinically delimiting the tumors in these cases, which
probably reflects the fact that the tumors tend to spread
widely and to include ‘‘skip areas’’, where the tumor is
present but is sometimes not as clinically visible as a typical
lesion (thin, pink, and scaly plaques). This fact probably
results in the surgeon removing a narrow initial margin in
the first stage of the MMS.
Sexton et al. described a series of 1039 consecutive
neoplasms in patients who underwent conventional surgery
and found that nodular and superficial basal cell carcinomas
were removed by simple surgical excisions in a high
percentage of these cases (93.6% and 96.4%) (11). This result
is probably because the patients underwent conventional
surgery and not MMS. During conventional surgery, the
surgeon tends to remove a larger margin (more than 4 mm),
mainly in areas where there is no need to save tissue, such
as the trunk, where superficial BCC is more common (8).
In contrast, when performing MMS, the surgeon removes a
Table 3 - Descriptive statistics by histological diagnosis.
Histological diagnosis Frequency % of
patients
(n=139)
% of the
histological
diagnoses
(n=199)
Nodular BCC 66 47.5 23.9
Infiltrative-growth BCC 47 33.8 17.0
Morpheaform BCC 39 28.1 14.1
Superficial BCC 16 11.5 5.8
Non specified BCC 15 10.8 5.4
Micronodular BCC 7 5.0 2.5
SCC 4 2.9 1.4
DFSP 2 1.4 0.7
Trichoblastoma 1 0.7 0.4
Fibrous histiocytoma 1 0.7 0.4
Primary cutaneous
adenocarcinoma
1 0.7 0.4
BCC: basal cell carcinoma; SCC: squamous cell carcinoma; DFSP: dermato-
fibrosarcoma protuberans.
Table 5 - The results of the binary logistic regression used to
evaluate factors associated with complications.
Simple analysis
Factor Effect vs. Ref Odds ratio IC 95%
(Odds ratio)
p-value
Nodular BCC Y vs. N 1.115 0.308 4.037 0.8686
Superficial BCC Y vs. N 6.500 1.607 26.298 0.0087
Infiltrative BCC Y vs. N 1.333 0.357 4.977 0.6685
Morpheaform BCC Y vs. N 1.790 0.477 6.725 0.3883
Micronodular BCC Y vs. N – – – –
Non-specified BCC Y vs. N – – – –
Age X71 vs. p70 2.308 0.632 8.428 0.2057
Multiple analysis
Factor Effect vs. Ref Odds ratio 95% CI
(Odds ratio)
p-value
Superficial BCC Y vs. N 6.500 1.607 26.298 0.0087
The histologic diagnoses that do not appear in the table were excluded
due to the low number of cases or because the patients did not present
any post-operative complications.
Table 4 - The logistic regression results used to evaluate the
association between the histologic diagnosis and number of
stages.
Simple analysis
Factor Effect vs. Ref Odds ratio 95% CI
(odds ratio)
p-value
Nodular BCC Y vs. N 1.784 0.930 3.422 0.0814
Superficial BCC Y vs. N 9.03 3.104 26.244 o0.0001
Infiltrative BCC Y vs. N 1.299 0.658 2.566 0.4508
Morpheaform BCC Y vs. N 1.497 0.732 3.062 0.2692
Micronodular BCC Y vs. N 0.914 0.208 4.020 0.9052
Non-specified BCC Y vs. N 0.382 0.117 1.243 0.1099
Multiple analysis
Factor Effect vs. Ref Odds ratio 95% CI
(odds ratio)
p-value
Superficial BCC Y vs. N 9.03 3.104 26.244 o.0001
The histologic diagnoses that do not appear in the table were excluded
due to the low number of cases.
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1 to 2 mm margin from the clinical lesion, making tumors with
indistinct clinical borders a challenge to excise in one stage.
The correlation between superficial BCC and complica-
tions was probably due to the higher number of stages
required for removal, which increases the length of the
surgery, resulting in a higher probability of bleeding and
therefore an increased likehood of necrosis.
In this study, recurrence was considered a late complica-
tion. Of the four cases of recurrence, two were superficial
BCC. Recurrence probably occurs due to the inadequate
excision of these tumors because the ‘‘skip areas’’ can create
the false impression of a free margin.
Some authors defend the use of topical 5% imiquimod or
photodynamic therapy (PDT) as an alternative treatment for
superficial BCC, especially for large superficial types and
multiple lesions and for patients who have contraindications
to surgical intervention (12–14). Although these less-aggressive
treatment options are available for patients with low-risk BCC,
surgery is still regarded as the gold standard (15–17).
Imiquimod 5% cream is a topical immune response
modifier that was approved by the US FDA in 1997 for the
treatment of genital and perianal warts (18). Its mechanism
of action is thought to involve the activation of macrophages
and other cells via binding to cell-surface receptors such as
the Toll-like receptor 7 (1). This stimulation of the innate and
cell-mediated immune responses leads to the generation of
antitumor and antivirus activity and it has been studied as a
treatment for superficial BCC, pigmented BCC and other
cutaneous neoplasms (18). Schulze et al. conducted a
randomized controlled trial of 166 patients that compared
the effects of 6 weeks of daily imiquimod administration to
those of a placebo. Histological tests at 12 weeks post-treatment
demonstrated that imiquimod displayed improved efficacy
over the placebo for treating superficial BCC (the histologic
clearance rate was 80% vs. 6%) (19).However, Bath-Hextall
et al. showed that the application of topical imiquimod was
inferior to surgery and presented no clear cosmetic or cost
benefits (15).
PDT is based on light activation of a photosensitizer localized
on the tumor tissue to generate highly reactive oxygen
intermediates that irreversibly oxidize essential cellular compo-
nents. This process causes tissue damage and necrosis and
induces apoptosis (20). Three randomized controlled studies
with long-term follow ups have compared the various effects of
PDT protocols to those of simple surgical excision protocols for
treating superficial BCC and primary nodular BCC. All of these
studies have demonstrated statistically superior clearance rates
for surgical excision over PDT (21–23).
As an option for obtaining better results and decreasing
morbidity, some authors have considered the possibility of
combined treatments that use topical chemotherapy with
MMS (24,25). Because this type of tumor can recur despite a
surgical excision with negative margins (because of its
tendency to produce a mosaic pattern with tumor-free
regions), we believe that association therapy is a good option
for treating superficial BCC. The topical treatment could be
used before MMS to reduce the size of the defect requiring
removal and the number of stages required during surgery
and it could be used after surgery to clear residual tumor
nests. Torres et al. reported on a randomized, double blind,
Figure 1 - Superficial basal cell carcinoma of the nose.
Figure 2 - Histological slides: Superficial basal cell carcinoma (yellow arrow). Left: toluidine blue stain. Right: hematoxylin and eosin
stain.
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vehicle-controlled study of imiquimod administered 5 days per
week for 2 to 6 weeks before MMS excision to remove
superficial BCC and nodular BCC. They showed that imiqui-
mod reduced the size of the target tumor and thereby resulted
in a smaller defect to be excised during MMS in subjects in the
4- and 6-week dosing regimens compared to the vehicle (26).
In conclusion, superficial BCC is unique, given its
propensity for ‘‘skip areas’’, recurrence and larger defects
than would be clinically expected. Further research is needed
to optimize treatment for these tumors and to decrease
morbidity in these patients.
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